| Literature DB >> 34838070 |
Qian Sun1, Jingchao Liu2, Lei Wu3, Yue Sun1, Jianrong Jin2, Sudan Wang1, Jing Wu1, Yang Jing3, Hui Zhou4, Chen Dong5.
Abstract
BACKGROUND: Serum lipid abnormalities are generally considered as a major risk factor for type 2 diabetes mellitus (T2DM). However, evidence for the effect of long-term serum lipid fluctuations on future T2DM probability remains limited.Entities:
Keywords: Association; Serum lipids; Trajectory; Type 2 diabetes mellitus; Visit-to-visit variability
Mesh:
Substances:
Year: 2021 PMID: 34838070 PMCID: PMC8627625 DOI: 10.1186/s12944-021-01592-9
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Baseline characteristics of the study population
| Variables | All participants | Diabetes | Non-diabetes | t/χ2 | |
|---|---|---|---|---|---|
| Age (years) | 50.39±7.98 | 52.12±7.03 | 50.30±8.02 | 3.32 | 0.001 |
| Male (%) | 3125 (69.83) | 191 (85.65) | 2934 (69.00) | 27.87 | < 0.001 |
| Body mass index (kg/m2) | 24.05±2.61 | 25.54±2.51 | 23.97±2.59 | 8.82 | < 0.001 |
| Smoking (%) | 1551 (34.66) | 118 (52.91) | 1433 (33.70) | 34.54 | < 0.001 |
| Drinking (%) | 1759 (39.31) | 97 (43.50) | 1662 (39.09) | 1.73 | 0.189 |
| Hypertension (%) | 568 (12.69) | 56 (25.11) | 512 (12.04) | 33.67 | < 0.001 |
| Antihypertensive drugs therapy (%) | 720 (16.09) | 54 (24.22) | 666 (15.66) | 11.48 | 0.001 |
| Systolic blood pressure (mmHg) | 115.41±12.81 | 121.17±13.07 | 115.11±12.72 | 6.93 | < 0.001 |
| Diastolic blood pressure (mmHg) | 75.64±9.39 | 80.52±9.73 | 75.38±9.30 | 8.02 | < 0.001 |
| FPG (mmol/L) | 5.33±0.44 | 5.91±0.47 | 5.30±0.42 | 20.99 | < 0.001 |
| TG (mmol/L) | 1.67±1.26 | 2.26±2.02 | 1.64±1.20 | 7.20 | < 0.001 |
| TC (mmol/L) | 4.92±0.85 | 5.14±0.97 | 4.91±0.84 | 3.92 | < 0.001 |
| LDL-c (mmol/L) | 3.04±0.76 | 3.26±0.86 | 3.03±0.75 | 4.37 | < 0.001 |
| HDL-c (mmol/L) | 1.35±0.34 | 1.20±0.28 | 1.35±0.34 | 6.52 | < 0.001 |
Associations of mean, visit-to-visit variability and trajectory of TG with incident T2DM
| TG | N (case) | Unadjusted HR (95 % CI) | Adjusted HR (95 % CI) | ||
|---|---|---|---|---|---|
| Mean level | |||||
| < 1.70 mmol/L | 2962 (94) | 1.00 (ref) | 1.00 (ref) | ||
| ≥1.70 mmol/L | 1513 (129) | 2.79 (2.14-3.64) | < 0.001 | 1.67 (1.25-2.21) | 0.000 |
| Total | |||||
| Quartiles of the mean level (mmol/L) | |||||
| Q1 (0.32,0.97) | 1106 (9) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (0.98,1.37) | 1146 (39) | 3.98 (1.93-8.22) | 0.000 | 3.38 (1.63-7.00) | 0.001 |
| Q3 (1.38,1.97) | 1107 (77) | 8.43 (4.22-16.81) | < 0.001 | 5.01 (2.47-10.15) | < 0.001 |
| Q4 (1.98,12.14) | 1116 (98) | 10.83 (5.47-21.44) | < 0.001 | 5.39 (2.66-10.90) | < 0.001 |
| < 0.001 | < 0.001 | < 0.001 | |||
| Per 1-unit increase | 1.41 (1.31-1.51) | < 0.001 | 1.26 (1.15-1.39) | < 0.001 | |
| Quartiles of SD | |||||
| Q1 (0.01,0.15) | 1093 (27) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (0.16,0.26) | 1164 (42) | 1.43 (0.88-2.32) | 0.149 | 1.20 (0.73-1.95) | 0.471 |
| Q3 (0.27,0.43) | 1078 (59) | 2.28 (1.45-3.60) | 0.000 | 1.60 (1.00-2.56) | 0.049 |
| Q4 (0.44,11.26) | 1140 (95) | 3.27 (2.13-5.02) | < 0.001 | 1.86 (1.20-2.89) | 0.006 |
| < 0.001 | < 0.001 | 0.014 | |||
| Trajectories | |||||
| Low | 3263 (113) | 1.00 (ref) | 1.00 (ref) | ||
Moderate Moderate-high | 980 (84) 200 (23) | 2.49 (1.88-3.30) 3.82 (2.44-5.99) | < 0.001 < 0.001 | 1.51 (1.12-2.03) 2.55 (1.62-4.03) | 0.007 < 0.001 |
| High | 32 (3) | 4.34 (1.37-13.71) | 0.012 | 1.93 (0.60-6.19) | 0.268 |
| < 0.001 | < 0.001 | 0.000 | |||
| Exclusion of prediabetes | |||||
| Quartiles of the mean level (mmol/L) | |||||
| Q1 (0.32,0.96) | 1061 (5) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (0.97,1.33) | 1045 (21) | 3.99 (1.51-10.59) | 0.005 | 3.58 (1.34-9.59) | 0.011 |
| Q3 (1.34,1.93) | 1047 (40) | 7.93 (3.13-20.10) | < 0.001 | 5.02 (1.92-13.11) | 0.001 |
| Q4 (1.94,12.14) | 1057 (51) | 10.46 (4.18-26.22) | < 0.001 | 5.62 (2.13-14.81) | 0.001 |
| Trajectories | |||||
| Low | 3056 (61) | 1.00 (ref) | 1.00 (ref) | ||
| Moderate | 940 (42) | 2.30 (1.55-3.41) | < 0.001 | 1.36 (0.88-2.08) | 0.163 |
| Moderate-high | 190 (12) | 3.55 (1.91-6.59) | < 0.001 | 2.43 (1.28-4.63) | 0.007 |
| High | 24 (2) | 6.72 (1.64-27.58) | 0.008 | 2.09 (0.48-9.03) | 0.324 |
Adjusted confounders including age, gender, BMI, smoking, drinking, baseline TC level, baseline FPG level and antihypertensive drugs therapy
Fig. 1Change trajectories of serum TG, TC, HDL-c and LDL-c during 2010-2013. (A: Change trajectories of TG, B: Change trajectories of TC, C: Change trajectories of LDL-c and D: Change trajectories of HDL-c)
Associations of mean, visit-to-visit variability and trajectory of TC with incident T2DM
| TC | N (case) | Unadjusted HR (95 % CI) | Adjusted HR (95 % CI) | ||
|---|---|---|---|---|---|
| Mean level | |||||
| < 5.18 mmol/L | 2915 (130) | 1.00 (ref) | 1.00 (ref) | ||
| ≥5.18 mmol/L | 1560 (93) | 1.35 (1.04-1.77) | 0.026 | 1.01 (0.77-1.33) | 0.926 |
| Total | |||||
| Quartiles of the mean level (mmol/L) | |||||
| Q1 (2.48,4.38) | 1114 (44) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (4.39,4.88) | 1126 (58) | 1.32 (0.89-1.95) | 0.166 | 1.07 (0.72-1.59) | 0.738 |
| Q3 (4.89,5.40) | 1113 (51) | 1.24 (0.83-1.85) | 0.305 | 0.98 (0.65-1.48) | 0.932 |
| Q4 (5.41,8.74) | 1122 (70) | 1.63 (1.11-2.37) | 0.012 | 1.07 (0.73-1.59) | 0.724 |
| 0.082 | 0.085 | 0.955 | |||
| Per 1-unit increase | 1.26 (1.07-1.48) | 0.006 | 1.01 (0.85-1.20) | 0.884 | |
| Quartiles of SD | |||||
| Q1 (0.02,0.23) | 1108 (47) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (0.24,0.34) | 1161 (52) | 1.14 (0.77-1.68) | 0.529 | 0.99 (0.66-1.47) | 0.944 |
| Q3 (0.35,0.47) | 1103 (44) | 1.04 (0.69-1.57) | 0.847 | 0.96 (0.63-1.45) | 0.834 |
| Q4 (0.48,2.02) | 1103 (80) | 1.79 (1.25-2.56) | 0.002 | 1.19 (0.83-1.72) | 0.350 |
| 0.001 | 0.003 | 0.598 | |||
| Trajectories | |||||
| Low | 1608 (69) | 1.00 (ref) | 1.00 (ref) | ||
| Moderate | 2212 (108) | 1.19 (0.88-1.61) | 0.263 | 0.98 (0.72-1.33) | 0.882 |
| High | 655 (46) | 1.74 (1.20-2.53) | 0.004 | 1.18 (0.80-1.74) | 0.406 |
| 0.024 | 0.014 | 0.565 | |||
| Exclusion of prediabetes | |||||
| Quartiles of the mean level (mmol/L) | |||||
| Q1 (2.48,4.37) | 1044 (21) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (4.38,4.87) | 1057 (30) | 1.41 (0.81-2.46) | 0.230 | 1.34 (0.76-2.35) | 0.315 |
| Q3 (4.88,5.39) | 1058 (22) | 1.10 (0.60-2.00) | 0.760 | 0.97 (0.53-1.78) | 0.921 |
| Q4 (5.40,8.74) | 1051 (44) | 2.12 (1.26-3.56) | 0.005 | 1.56 (0.91-2.67) | 0.109 |
| Trajectories | |||||
| Low | 749 (13) | 1.00 (ref) | 1.00 (ref) | ||
| Moderate | 1767 (46) | 1.52 (0.82-2.81) | 0.185 | 1.26 (0.68-2.36) | 0.466 |
| Moderate-high | 1373 (43) | 1.86 (1.00-3.47) | 0.049 | 1.35 (0.71-2.56) | 0.364 |
| High | 321 (15) | 2.81 (1.34-5.90) | 0.007 | 1.76 (0.82-3.79) | 0.150 |
Adjusted confounders including age, gender, BMI, smoking, drinking, baseline TG level, baseline FPG level and antihypertensive drugs therapy
Associations of mean, visit-to-visit variability and trajectory of LDL-c with incident T2DM
| LDL-c | N (case) | Unadjusted HR (95 % CI) | Adjusted HR (95 % CI) | ||
|---|---|---|---|---|---|
| Mean level | |||||
| < 3.37 mmol/L | 3354 (145) | 1.00 (ref) | 1.00 (ref) | ||
| ≥3.37 mmol/L | 1121 (78) | 1.54 (1.17-2.03) | 0.002 | 1.12 (0.85-1.49) | 0.426 |
| Total | |||||
| Quartiles of the mean level (mmol/L) | |||||
| Q1 (0.00,2.49) | 1125 (44) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (2.50,2.92) | 1109 (47) | 1.16 (0.77-1.75) | 0.477 | 1.02 (0.68-1.55) | 0.920 |
| Q3 (2.93,3.37) | 1119 (54) | 1.25 (0.84-1.87) | 0.265 | 1.09 (0.73-1.63) | 0.684 |
| Q4 (3.38,6.57) | 1122 (78) | 1.75 (1.21-2.53) | 0.003 | 1.16 (0.80-1.70) | 0.432 |
| 0.004 | 0.015 | 0.848 | |||
| Per 1-unit increase | 1.30 (1.08-1.56) | 0.005 | 1.02 (0.84-1.23) | 0.859 | |
| Quartiles of SD | |||||
| Q1 (0.01,0.21) | 1107 (39) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (0.22,0.30) | 1084 (50) | 1.36 (0.90-2.07) | 0.146 | 1.30 (0.85-1.98) | 0.224 |
| Q3 (0.31,0.42) | 1195 (59) | 1.41 (0.94-2.11) | 0.098 | 1.09 (0.72-1.63) | 0.688 |
| Q4 (0.43,1.71) | 1084 (75) | 1.87 (1.27-2.75) | 0.002 | 1.18 (0.80-1.76) | 0.404 |
| 0.003 | 0.016 | 0.633 | |||
| Trajectories | |||||
| Low | 648 (30) | 1.00 (ref) | 1.00 (ref) | ||
| Moderate | 1915 (79) | 0.95 (0.62-1.45) | 0.808 | 0.78 (0.51-1.19) | 0.250 |
| Moderate-high | 1527 (86) | 1.23 (0.81-1.86) | 0.337 | 0.91 (0.59-1.38) | 0.642 |
| High | 3385 (28) | 1.51 (0.90-2.53) | 0.116 | 0.86 (0.51-1.45) | 0.574 |
| 0.033 | 0.124 | 0.654 | |||
| Exclusion of prediabetes | |||||
| Quartiles of the mean level (mmol/L) | |||||
| Q1 (0.00,2.49) | 1064 (20) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (2.50,2.92) | 1057 (25) | 1.34 (0.75-2.42) | 0.328 | 1.15 (0.64-2.08) | 0.647 |
| Q3 (2.93,3.36) | 1034 (26) | 1.34 (0.75-2.39) | 0.331 | 1.16 (0.65-2.09) | 0.617 |
| Q4 (3.37,6.57) | 1055 (46) | 2.28 (1.35-3.86) | 0.002 | 1.63 (0.95-2.78) | 0.074 |
| Trajectories | |||||
| Low | 609 (15) | 1.00 (ref) | 1.00 (ref) | ||
| Moderate | 1797 (36) | 0.86 (0.47-1.57) | 0.623 | 0.76 (0.41-1.39) | 0.372 |
| Moderate-high | 1448 (48) | 1.34 (0.75-2.39) | 0.322 | 1.02 (0.57-1.84) | 0.944 |
| High | 356 (18) | 2.01 (1.01-3.99) | 0.046 | 1.31 (0.65-2.62) | 0.451 |
Adjusted confounders including age, gender, BMI, smoking, drinking, baseline TG level, baseline FPG level and antihypertensive drugs therapy
Associations of mean, visit-to-visit variability and trajectory of HDL-c with incident T2DM
| HDL-c | N (case) | Unadjusted HR (95 % CI) | Adjusted HR (95 % CI) | ||
|---|---|---|---|---|---|
| Mean level | |||||
| >1.04 mmol/L | 3532 (141) | 1.00 (ref) | 1.00 (ref) | ||
| ≤1.04 mmol/L | 943 (82) | 2.37 (1.80-3.11) | < 0.001 | 1.28 (0.95-1.72) | 0.109 |
| Total | |||||
| Quartiles of the mean level (mmol/L) | |||||
| Q1 (0.00,1.07) | 1141 (98) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (1.08,1.25) | 1101 (65) | 0.68 (0.49-0.93) | 0.001 | 0.89 (0.65-1.24) | 0.495 |
| Q3 (1.26,1.50) | 1125 (41) | 0.37 (0.25-0.53) | < 0.001 | 0.55 (0.37-0.80) | 0.002 |
| Q4 (1.51,2.95) | 1108 (19) | 0.19 (0.11-0.31) | < 0.001 | 0.38 (0.22-0.66) | 0.001 |
| < 0.001 | < 0.001 | 0.001 | |||
| Per 1-unit increase | 0.14 (0.09-0.23) | < 0.001 | 0.35 (0.20-0.63) | 0.000 | |
| Quartiles of SD | |||||
| Q1 (0.01,0.07) | 1056 (60) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (0.08,0.10) | 1012 (59) | 0.93 (0.65-1.33) | 0.675 | 0.92 (0.64-1.32) | 0.650 |
| Q3 (0.11,0.15) | 1310 (60) | 0.70 (0.49-1.01) | 0.054 | 0.90 (0.63-1.30) | 0.571 |
| Q4 (0.16,0.52) | 1092 (44) | 0.56 (0.38-0.83) | 0.004 | 0.78 (0.52-1.17) | 0.234 |
| 0.160 | 0.014 | 0.699 | |||
| Trajectories | |||||
| Low | 2244 (164) | 1.00 (ref) | 1.00 (ref) | ||
| Moderate | 1680 (51) | 0.38 (0.27-0.51) | < 0.001 | 0.52 (0.37-0.72) | < 0.001 |
| High | 551 (8) | 0.18 (0.09-0.36) | < 0.001 | 0.38 (0.18-0.80) | 0.011 |
| < 0.001 | < 0.001 | < 0.001 | |||
| Exclusion of prediabetes | |||||
| Quartiles of the mean level (mmol/L) | |||||
| Q1 (0.00,1.07) | 1039 (50) | 1.00 (ref) | 1.00 (ref) | ||
| Q2 (1.08,1.26) | 1064 (34) | 0.65 (0.42-1.01) | 0.053 | 0.90 (0.57-1.41) | 0.645 |
| Q3 (1.27,1.51) | 1077 (23) | 0.39 (0.24-0.64) | 0.000 | 0.57 (0.33-0.97) | 0.040 |
| Q4 (1.52,2.95) | 1030 (10) | 0.19 (0.09-0.37) | < 0.001 | 0.35 (0.16-0.75) | 0.007 |
| Trajectories | |||||
| Low | 2100 (83) | 1.00 (ref) | 1.00 (ref) | ||
| Moderate | 1588 (29) | 0.42 (0.28-0.64) | < 0.001 | 0.55 (0.35-0.88) | 0.013 |
| High | 522 (5) | 0.21 (0.09-0.53) | 0.001 | 0.40 (0.15-1.04) | 0.061 |
Adjusted confounders including age, gender, BMI, smoking, drinking, baseline TG level, baseline FPG level and antihypertensive drugs therapy